• Publications
  • Influence
Advanced therapy medicinal products: current and future perspectives
TLDR
Although most of the products are in an early development phase, the combined trial phase and the potential to cure severe chronic conditions suggest that ATMPs may reach the market earlier than standard therapies. Expand
Overview of external reference pricing systems in Europe
TLDR
While ERP is widely used in Europe, processes and availability of price information vary from one country to another, thus limiting ERP implementation. Expand
Supply-side and demand-side policies for biosimilars: an overview in 10 European member states
TLDR
Important heterogeneity in policies on biosimilars was seen between (and even within) selected countries, which may partly explain variations in biosimilar uptake. Expand
Key drivers for market penetration of biosimilars in Europe
TLDR
Understanding drivers of biosimilar uptake becomes a critical issue to inform policy decision-makers and showed that incentive policies to enhance uptake remain an important driver of biosimilars penetration, while biosimilar price discounts have no impact. Expand
Filling the gap in CNS drug development: evaluation of the role of drug repurposing
TLDR
Repurposing drugs into CNS is an efficient and very active drug development method, exemplified by the considerable number of new indications that have been found via this strategy, with approximately half of the target indications currently under development. Expand
Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey
TLDR
The French public draws a clear line between schizophrenia and major depressive disorder, which applies equally to beliefs about both disorders and to attitudes towards the persons afflicted. Expand
New drug regulations in France: what are the impacts on market access? Part 1 – Overview of new drug regulations in France
TLDR
The severity of the condition being treated, which used to be the main determinant of the drug's reimbursement level in France, has now been replaced with the drugs’ efficacy criterion and the effect size required for acknowledging drug innovation has substantially increased. Expand
Value added medicines: what value repurposed medicines might bring to society?
TLDR
There is currently a gap between increasing regulatory authority interest in capturing value added medicines’ benefits and the resistance of HTA bodies/payers, who tend to ignore this important segment of the pharmaceutical field, and policy changes are needed to foster appropriate incentives to enhance value recognition ofvalue added medicines and deliver the expected benefit to society. Expand
Gene therapies development: slow progress and promising prospect
TLDR
The first gene therapy was approved in the European Union in 2012, after two decades of dashed expectations, boosted the investment in developing gene therapies and anticipated market launch in the upcoming years. Expand
Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder
TLDR
Some inconsistencies in psychiatrists' routine clinical evaluation of cognitive function are revealed, including low use of true cognitive assessment instruments in clinical practice and confusion regarding what constituted a cognitive assessment instrument. Expand
...
1
2
3
4
5
...